KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Astrazeneca (AZN) over the last 17 years, with Q4 2025 value amounting to $5.7 billion.

  • Astrazeneca's Cash & Equivalents rose 406.34% to $5.7 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $5.7 billion, marking a year-over-year increase of 406.34%. This contributed to the annual value of $5.7 billion for FY2025, which is 406.34% up from last year.
  • As of Q4 2025, Astrazeneca's Cash & Equivalents stood at $5.7 billion, which was up 406.34% from $8.1 billion recorded in Q3 2025.
  • Over the past 5 years, Astrazeneca's Cash & Equivalents peaked at $15.6 billion during Q2 2021, and registered a low of $4.5 billion during Q3 2022.
  • Over the past 5 years, Astrazeneca's median Cash & Equivalents value was $6.0 billion (recorded in 2022), while the average stood at $6.6 billion.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first skyrocketed by 28048.19% in 2021, then tumbled by 6905.63% in 2022.
  • Astrazeneca's Cash & Equivalents (Quarter) stood at $6.3 billion in 2021, then fell by 2.58% to $6.2 billion in 2022, then fell by 5.29% to $5.8 billion in 2023, then dropped by 6.03% to $5.5 billion in 2024, then rose by 4.06% to $5.7 billion in 2025.
  • Its Cash & Equivalents was $5.7 billion in Q4 2025, compared to $8.1 billion in Q3 2025 and $7.1 billion in Q2 2025.